Clinical Trials
Nivolumab Plus deb-TACE in Unresectable Liver-Limited Hepatocellular Carcinoma
Harding et alESMO Gastrointest Oncol

This multicenter phase I trial evaluated the safety, efficacy, and immune impact of adding nivolumab to drug-eluting bead transarterial chemoembolization (deb-TACE) in patients with unresectable, liver-limited hepatocellular carcinoma (HCC). Using a 3 + 3 dose-escalation and expansion design across three dosing schedules, 19 patients received deb-TACE alongside nivolumab (240 mg intravenously every 2 weeks) for up to 1 year. The primary objective was safety assessment, while secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and exploratory immunological markers.
The combination exhibited acceptable overall tolerability across all dosing cohorts. Only one dose-limiting toxicity—a grade 3 transaminitis—was reported; it resolved spontaneously without clinical intervention and did not recur following treatment rechallenge. The most frequently observed treatment-related adverse events included fatigue (53%), transaminase elevation (42%), and fever (37%). Exploratory analyses of peripheral T-cell subsets and cytokines identified transient immunological alterations, though these changes lacked statistical significance and did not exert persistent immune-modulatory effects.
Regarding clinical activity, the ORR was 21% (95% CI, 6%–44%). Over a median follow-up period of 72.7 months, the median PFS was 5.9 months (95% CI, 3.6–23) and median OS reached 23.0 months (95% CI, 19–62). Despite meeting safety endpoints, the trial demonstrated that combining nivolumab with deb-TACE did not meaningfully enhance antitumor efficacy compared to historical controls receiving deb-TACE alone. These results align with broader phase III data showing limited survival advantage for chemoembolization combined with single-agent immune checkpoint blockade, highlighting the necessity for hypothesis-driven trial designs, superior patient stratification, and alternative therapeutic combinations in localized HCC.
Key Takeaways
- In a phase I trial of 19 patients with unresectable, liver-limited hepatocellular carcinoma treated with nivolumab and drug-eluting bead transarterial chemoembolization (deb-TACE), the objective response rate was 21% (95% CI, 6%–44%), with a median progression-free survival of 5.9 months (95% CI, 3.6–23) and a median overall survival of 23.0 months (95% CI, 19–62) over a median follow-up of 72.7 months.
- The combination demonstrated acceptable safety with one dose-limiting toxicity (grade 3 transaminitis) that resolved without intervention and did not recur upon rechallenge; the most frequent treatment-related adverse events were fatigue (53%), transaminase elevation (42%), and fever (37%).
- Nivolumab plus deb-TACE failed to improve antitumor efficacy beyond historical benchmarks for deb-TACE monotherapy, underscoring the need for improved biomarker selection and alternative combination strategies in localized hepatocellular carcinoma.
Read the original sourceESMO Gastrointest Oncol
